Leukemia Research
Volume 29, Issue 7 , Pages 723-726 , July 2005

Experimental myelofibrosis in mice and the implications to human disease

Received 4 October 2004 ,Accepted 8 December 2004.

References 

  1. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med. 2000;342:1255–1265
  2. Reeder TL, Bailey RJ, Dewald GW, Tefferi A. Both B and T lymphocytes may be clonally involved in myelofibrosis with myeloid metaplasia. Blood. 2003;101:1981–1983
  3. Martyre MC. Critical review of pathogenetic mechanisms in myelofibrosis with myeloid metaplasia. Curr Hematol Rep. 2003;2:257–263
  4. Terui T, Niitsu Y, Mahara K, Fujisaki Y, Urushizaki Y, Mogi Y, et al. The production of transforming growth factor-beta in acute megakaryoblastic leukemia and its possible implications in myelofibrosis. Blood. 1990;75:1540–1548
  5. Martyre MC, Romquin N, Le Bousse-Kerdiles MC, Chevillard S, Benyahia B, Dupriez B, et al. Transforming growth factor-beta and megakaryocytes in the pathogenesis of idiopathic myelofibrosis. Br J Haematol. 1994;88:9–16
  6. Martyre MC, Magdelenat H, Bryckaert MC, Laine-Bidron C, Calvo F. Increased intraplatelet levels of platelet-derived growth factor and transforming growth factor-beta in patients with myelofibrosis with myeloid metaplasia. Br J Haematol. 1991;77:80–86
  7. Le Bousse-Kerdiles MC, Chevillard S, Charpentier A, Romquin N, Clay D, Smadja-Joffe F, et al. Differential expression of transforming growth factor-beta, basic fibroblast growth factor, and their receptors in CD34+ hematopoietic progenitor cells from patients with myelofibrosis and myeloid metaplasia. Blood. 1996;88:4534–4546
  8. Le Bousse-Kerdiles MC, Martyre MC, French IrnoIM. Involvement of the fibrogenic cytokines, TGF-beta and bFGF, in the pathogenesis of idiopathic myelofibrosis. Pathologie et Biologie. 2001;49:153–157
  9. Martyre MC, Le Bousse-Kerdiles MC, Romquin N, Chevillard S, Praloran V, Demory JL, et al. Elevated levels of basic fibroblast growth factor in megakaryocytes and platelets from patients with idiopathic myelofibrosis. Br J Haematol. 1997;97:441–448
  10. Katoh O, Kimura A, Itoh T, Kuramoto A. Platelet derived growth factor messenger RNA is increased in bone marrow megakaryocytes in patients with myeloproliferative disorders. Am J Hematol. 1990;35:145–150
  11. Rameshwar P, Denny TN, Stein D, Gascon P. Monocyte adhesion in patients with bone marrow fibrosis is required for the production of fibrogenic cytokines. Potential role for interleukin-1 and TGF-beta. J Immunol. 1994;153:2819–2830
  12. Castro-Malaspina H, Gay RE, Jhanwar SC, Hamilton JA, Chiarieri DR, Meyers PA, et al. Characteristics of bone marrow fibroblast colony-forming cells (CFU-F) and their progeny in patients with myeloproliferative disorders. Blood. 1982;59:1046–1054
  13. Greenberg BR, Woo L, Veomett IC, Payne CM, Ahmann FR. Cytogenetics of bone marrow fibroblastic cells in idiopathic chronic myelofibrosis. Br J Haematol. 1987;66:487–490
  14. Yonekura S, Nagao T, Nozaki H, Arimori S. Increased collagen synthesis of bone marrow fibroblasts by materials released from platelets of chronic granulocytic leukemia and polycythemia vera. Acta Haematol. 1986;75:6–11
  15. Han ZC, Briere J, Parent D, Abgrall JF, Sensebe L. Increased fibroblast colony stimulating activity (F-CSA) in serum of myeloproliferative disorders. J Biol Regul Homeostatic Agents. 1988;2:119–124
  16. Bauldry SA, Wilson FD, Stromberg PC, Ackerman GA. Stimulation of normal rat bone marrow fibroblast proliferation by sera from leukemic Fischer rats. Exp Hematol. 1985;13:750–759
  17. Eid J, Ebert RF, Gesell MS, Spivak JL. Intracellular growth factors in polycythemia vera and other myeloproliferative disorders. Proc Natl Acad Sci USA. 1987;84:532–536
  18. Schmitt A, Jouault H, Guichard J, Wendling F, Drouin A, Cramer EM. Pathologic interaction between megakaryocytes and polymorphonuclear leukocytes in myelofibrosis. Blood. 2000;96:1342–1347
  19. Centurione L, Di Baldassarre A, Zingariello M, Bosco D, Gatta V, Rana RA, et al. Increased and pathological emperipolesis of neutrophils within megakaryocytes associated with marrow fibrosis in GATA-1low mice. Blood. 2004;
  20. Le Bousse-Kerdiles MC, Souyri M, Smadja-Joffe F, Praloran V, Jasmin C, Ziltener HJ. Enhanced hematopoietic growth factor production in an experimental myeloproliferative syndrome. Blood. 1992;79:3179–3187
  21. Zupanska B, Szmigielski S, Litwin J, Zielinski J. Cytoenzymatic changes in the course of experimental osteomyelosclerosis in rats. Arch Immunol Ther Exp (Warsz). 1966;14:356–362
  22. Stodtmeister R, Becker H, Cronkite EP, Fliedner TM, Messner H. Experimental bone marrow fibrosis in rats following sublethal whole-body X-ray irradiation and bone marrow transfusions as a model of human myelofibrosis. Schweiz Med Wochenschr. 1968;98:1671–1673
  23. Van Gorp LH, Swaen GJ. Myelofibrosis in rats experimentally infected with a murine leukaemia virus. J Pathol. 1969;97:235–240
  24. Takacsi-Nagy L, Juhasz J. Experimental myelosclerosis. Haematologia (Budap). 1971;5:283–291
  25. Stodtmeister R, Fliedner TM. Morphological aspects of myelofibrosis, observed in rats following sublethal whole body irradiation and subsequent allogeneic bone marrow cell transfusion. Folia Haematol Int Mag Klin Morphol Blutforsch. 1973;100:23–50
  26. Hunstein W. Experimental myelofibrosis. Clin Haematol. 1975;4:457–478
  27. Ebbe S. Experimental and clinical megakaryocytopoiesis. Clin Haematol. 1979;8:371–394
  28. Ruddle NH, Li CB, Horne WC, Santiago P, Troiano N, Jay G, et al. Mice transgenic for HTLV-I LTR-tax exhibit tax expression in bone, skeletal alterations, and high bone turnover. Virology. 1993;197:196–204
  29. Yan XQ, Lacey D, Fletcher F, Hartley C, McElroy P, Sun Y, et al Chronic exposure to retroviral vector encoded MGDF (mpl-ligand) induces lineage-specific growth and differentiation of megakaryocytes in mice. Blood. 1995;86:4025–4033
  30. Yan XQ, Lacey D, Hill D, Chen Y, Fletcher F, Hawley RG, et al. A model of myelofibrosis and osteosclerosis in mice induced by overexpressing thrombopoietin (mpl ligand): reversal of disease by bone marrow transplantation. Blood. 1996;88:402–409
  31. Yanagida M, Ide Y, Imai A, Toriyama M, Aoki T, Harada K, et al. The role of transforming growth factor-beta in PEG-rHuMGDF-induced reversible myelofibrosis in rats. Br J Haematol. 1997;99:739–745
  32. Villeval JL, Cohensolal K, Tulliez M, Giraudier S, Guichard J, Burstein SA, et al. High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice. Blood. 1997;90:4369–4383
  33. Vannucchi AM, Bianchi L, Cellai C, Paoletti F, Rana RA, Lorenzini R, et al. Development of myelofibrosis in mice genetically impaired for GATA-1 expression (GATA-1(low) mice). Blood. 2002;100:1123–1132
  34. Kaushansky K. Thrombopoietin: the primary regulator of platelet production. Blood. 1995;86:419–431
  35. Vyas P, Ault K, Jackson CW, Orkin SH, Shivdasani RA. Consequences of GATA-1 deficiency in megakaryocytes and platelets. Blood. 1999;93:2867–2875
  36. Zhou W, Toombs CF, Zou T, Guo J, Robinson MO. Transgenic mice overexpressing human C-Mpl ligand exhibit chronic thrombocytosis and display enhanced recovery from 5-fluorouracil or antiplatelet serum treatment. Blood. 1997;89:1551–1559
  37. Frey BM, Rafii S, Teterson M, Eaton D, Crystal RG, Moore MA. Adenovector-mediated expression of human thrombopoietin cDNA in immune- compromised mice: insights into the pathophysiology of osteomyelofibrosis. J Immunol. 1998;160:691–699
  38. Abina MA, Tulliez M, Lacout C, Debili N, Villeval JL, Pflumio F, et al. Major effects of TPO delivered by a single injection of a recombinant adenovirus on prevention of septicemia and anemia associated with myelosuppression in mice: risk of sustained expression inducing myelofibrosis due to immunosuppression. Gene Ther. 1998;5:497–506
  39. Ulich TR, Delcastillo J, Senaldi G, Kinstler O, Yin SM, Kaufman S, et al. Systemic hematologic effects of Peg-Rhumgdf-induced megakaryocyte hyperplasia in mice. Blood. 1996;87:5006–5015
  40. Chagraoui H, Komura E, Tulliez M, Giraudier S, Vainchenker W, Wendling F. Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice. Blood. 2002;100:3495–3503
  41. Chagraoui H, Tulliez M, Smayra T, Komura E, Giraudier S, Yun T, et al. Stimulation of osteoprotegerin production is responsible for osteosclerosis in mice overexpressing TPO. Blood. 2003;101:2983–2989
  42. Vannucchi A, Bianchi L, Laurenzana A, Paoletti F, Rana R, Marsilli L, et al. In vivo treatment with thrombopoietin corrects the thrombocytopenia and does not accelerate the progression of myelofibrosis in GATA-1low mice. Exp Hematol. 2003;31:186–187
  43. Vannucchi A, Bianchi L, Paoletti F, Di Giacomo V, Migliaccio G, Migliaccio AR. Impaired GATA-1 expression and myelofibrosis in an animal model. Pathol Biol. 2004;52:275–279
  44. Shehata M, Schwarzmeier JD, Hilgarth M, Hubmann R, Duechler M, Gisslinger H. TGF-beta1 induces bone marrow reticulin fibrosis in hairy cell leukemia. J Clin Invest. 2004;113:676–685
  45. Harrison CN, Gale RE, Wiestner AC, Skoda RC, Linch DC. The activating splice mutation in intron 3 of the thrombopoietin gene is not found in patients with non-familial essential thrombocythaemia. Br J Haematol. 1998;102:1341–1343
  46. Taksin AL, Couedic JPL , Dusanter-Fourt I, Masse A, Giraudier S, Katz A, et al. Autonomous megakaryocyte growth in essential thrombocythemia and idiopathic myelofibrosis is not related to a c-mpl mutation or to an autocrine stimulation by Mpl-L. Blood. 1999;93:125–139
  47. Kiladjian JJ, Elkassar N, Hetet G, Briere J, Grandchamp B, Gardin C. Study of the thrombopoietin receptor in essential thrombocythemia. Leukemia. 1997;11:1821–1826
  48. Martyre MC, Steunou V, LeBousse-Kerdiles MC, Wietzerbin J. Lack of alteration in GATA-1 expression in CD34+ hematopoietic progenitors from patients with idiopathic myelofibrosis. Blood 2003;101:5087–8; author reply 5088–9.
  49. Gandini D, Allen AJ, Nash MJ, Linch DC, Gale RE. No mutations in the gata-1 gene detected in patients with acquired essential thrombocythemia. Haematologica. 2004;89:613–615
  50. Fisher C, Steensma D, Janmohamed R, Kaczmarski R, Reilly JT, Vyas P. Absence of mutations in the key megakaryocyte transcriptional regulator FOG-1 in patients with idiopathic myelofibrosis. Br J Haematol. 2004;126:750–752
  51. Greene ME, Mundschau G, Wechsler J, McDevitt M, Gamis A, Karp J, et al. Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome. Blood Cells Mol Dis. 2003;31:351–356
  52. Mehaffey MG, Newton AL, Gandhi MJ, Crossley M, Drachman JG. X-linked thrombocytopenia caused by a novel mutation of GATA-1. Blood. 2001;98:2681–2688
  53. Wiestner A, Schlemper RJ, Vandermaas APC , Skoda RC. An activating splice donor mutation in the thrombopoietin gene causes hereditary thrombocythaemia. Nat Genet. 1998;18:49–52
  54. Ding J, Komatsu H, Wakita A, Kato-Uranishi M, Ito M, Satoh A, et al. Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood. 2004;103:4198–4200
  55. Ghilardi N, Skoda RC. A single-base deletion in the thrombopoietin (TPO) gene causes familial essential thrombocythemia through a mechanism of more efficient translation of TPO mRNA [letter]. Blood. 1999;94:1480–1482
  56. Kondo T, Okabe M, Sanada M, Kurosawa M, Suzuki S, Kobayashi M, et al. Familial essential thrombocythemia associated with one-base deletion in the 5′-untranslated region of the thrombopoietin gene. Blood. 1998;92:1091–1096
  57. Ihara K, Ishii E, Eguchi M, Takada H, Suminoe A, Good RA, et al. Identification of mutations in the c-mpl gene in congenital amegakaryocytic thrombocytopenia. Proc Natl Acad Sci USA. 1999;96:3132–3136
  58. Ballmaier M, Germeshausen M, Schulze H, Cherkaoui K, Lang S, Gaudig A, et al. c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia. Blood. 2001;97:139–146
  59. van den Oudenrijn S, Bruin M, Folman CC, Peters M, Faulkner LB, de Haas M, et al. Mutations in the thrombopoietin receptor, Mpl, in children with congenital amegakaryocytic thrombocytopenia. Br J Haematol. 2000;110:441–448

PII: S0145-2126(05)00028-7

doi: 10.1016/j.leukres.2004.12.006

Leukemia Research
Volume 29, Issue 7 , Pages 723-726 , July 2005

Article Tools